促性腺激素释放激素类似物对接受化疗的中国绝经前乳腺癌女性卵巢功能的保护作用:一项随机临床试验
这项开放标签随机临床试验在中国两家医院纳入330例可手术I-III期绝经前乳腺癌患者,评估化疗期间使用GnRHa能否减少卵巢损伤。结果显示化疗后12个月GnRHa组POI率为10.3%,对照组为44.5%(OR 0.23,95%CI 0.14-0.39,P<.001),GnRHa组抗苗勒管激素恢复也显著优于对照组;两组4年OS和TFS无显著差异。
要点
- 化疗后12个月POI率:GnRHa组10.3%(15/146)vs 对照组44.5%(69/155),OR 0.23(95%CI 0.14-0.39,P<.001)。
- 抗苗勒管激素恢复:GnRHa组15/25 vs 对照组6/44,OR 4.40(95%CI 1.96-9.89,P<.001)。
- 中位随访49个月,两组4年OS和TFS差异无统计学意义。
核心结论
- 在绝经前乳腺癌患者化疗期间给予GnRHa可降低POI风险并促进卵巢功能恢复。
研究设计与样本
- 开放标签随机临床试验,在中国上海交通大学附属第六人民医院和浙江省肿瘤医院开展。
- 纳入18至49岁可手术I至III期、计划接受含环磷酰胺辅助或新辅助化疗的绝经前乳腺癌女性,1:1随机分为化疗联合GnRHa组(n=165)和单纯化疗组(n=165)。
- 2015年9月至2017年8月入组,随访至2020年12月,2021年3月分析数据;共405例入组,27例(6.7%)自愿退出,33例(8.1%)不符合纳入标准被排除,15例(3.7%)失访,最终330例纳入主要分析,其中29例基线抗苗勒管激素低于0.5 ng/mL。
主要发现
- 化疗结束后12个月POI率:GnRHa组10.3%(15/146)vs 对照组44.5%(69/155),OR 0.23(95%CI 0.14-0.39,P<.001)。
- 抗苗勒管激素恢复:GnRHa组15/25 vs 对照组6/44,OR 4.40(95%CI 1.96-9.89,P<.001)。
- 中位随访49个月(范围25-60个月),两组4年OS和TFS差异无统计学意义。
- 事后分析显示,在35岁以下患者中,GnRHa组TFS高于对照组(93% vs 62%;P=.004;HR 0.15,95%CI 0.03-0.82,P=.03)。
关键数值与推荐
- POI定义为本研究中抗苗勒管激素水平低于0.5 ng/mL。
- GnRHa组从化疗第一周期前1至2周至末次化疗后4周,每28天皮下注射戈舍瑞林3.6 mg或亮丙瑞林3.75 mg。
临床怎么用
- 作者结论认为,对绝经前乳腺癌患者化疗期间给予GnRHa可降低POI风险并促进卵巢功能恢复。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Studies of the use of gonadotropin-releasing hormone analogs (GnRHa) to protect ovarian function have shown mixed results. OBJECTIVE: To determine whether administering GnRHa during chemotherapy in premenopausal women with breast cancer can reduce ovarian impairment. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial, conducted at the Shanghai Jiao Tong University Affiliated Shanghai Sixth People's Hospital and Zhejiang Cancer Hospital in China, was an open-label trial involving premenopausal women aged 18 to 49 years with operable stage I to III breast cancer for which treatment with adjuvant or neoadjuvant cyclophosphamide-containing chemotherapy was planned in 2 parallel groups: treatment with chemotherapy with or without GnRHa. Enrollment occurred from September 2015 to August 2017, and follow-up ended December 2020. The data were analyzed in March 2021. A total of 405 patients were enrolled in the study, among whom 27 patients (6.7%) quit participation voluntarily, 33 (8.1%) did not meet the inclusion criteria and were excluded, and 15 (3.7%) were lost to follow-up. Ultimately 330 patients were included in the primary analysis, including 29 patients with baseline anti-Müllerian hormone levels less than 0.5ng/ mL. INTERVENTIONS: Eligible patients were randomly assigned (1:1) to receive chemotherapy with (n = 165) or without (n = 165) GnRHa. In patients randomized to receive GnRHa, 3.6 mg of goserelin or 3.75 mg of leuprorelin was injected subcutaneously once every 28 days from 1 to 2 weeks before the first cycle of chemotherapy to 4 weeks after the last cycle of chemotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was the rate of premature ovarian insufficiency (POI) at 12 months after chemotherapy. Premature ovarian insufficiency was defined as anti-Müllerian hormone levels of less than 0.5 ng/mL in this study. The secondary end point was overall survival (OS) and tumor-free survival (TFS). RESULTS: A total of 330 eligible patients could be evaluated with complete data, among whom 301 patients (91.2%; GnRHA group: mean [SD] age, 40.6 [6.7] years; control group: mean [SD] age, 40.2 [5.9] years) were eligible for primary end point analysis. At 12 months after the completion of chemotherapy, the POI rate was 10.3% (15 of 146) in the GnRHa group and 44.5% (69 of 155) in the control group (odds ratio, 0.23; 95% CI, 0.14-0.39; P < .001). Anti-Müllerian hormone resumption in the GnRHa group was significantly better than that in the control group (15 of 25 vs 6 of 44; odds ratio, 4.40; 95% CI, 1.96-9.89; P < .001). After a median follow-up of 49 months (range, 25-60 months), the differences in 4-year OS and TFS between the 2 groups were not significant. A post hoc analysis showed that in patients younger than 35 years, the TFS was higher in the GnRHa group than in the control group (93% vs 62%; P = .004; hazard ratio, 0.15; 95% CI, 0.03-0.82; P = .03). CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that administering GnRHa in treatment with chemotherapy for premenopausal patients with breast cancer reduces the risk of POI, which promotes the recovery of ovarian function. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02518191.
引用
- Zong X, Yu Y, Yang H, et al. Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 34967844. doi:10.1001/jamaoncol.2021.6214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。